Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Cushing's Syndrome

Interventions

DRUG: CORT125134

Sponsor

Corcept Therapeutics